Journal of Experimental Pharmacology (Aug 2020)
New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties
Abstract
Chungping Yu,1 Jennie Garcia-Olivares,1 Shawn Candler,1 Stefan Schwabe,1 Vladimir Maletic2 1Supernus Pharmaceuticals, Inc., Rockville, MD, USA; 2Department of Psychiatry/Behavioral Science, University of South Carolina School of Medicine, Greenville, SC, USACorrespondence: Chungping YuSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD 20850, USATel +1 301 838 2679Email [email protected]: Viloxazine was historically described as a norepinephrine reuptake inhibitor (NRI). Since NRIs have previously demonstrated efficacy in attention deficit/hyperactivity disorder (ADHD), viloxazine underwent contemporary investigation in the treatment of ADHD. Its clinical and safety profile, however, was found to be distinct from other ADHD medications targeting norepinephrine reuptake. Considering the complexity of neuropsychiatric disorders, understanding the mechanism of action (MoA) is an important differentiating point between viloxazine and other ADHD medications and provides pharmacology-based rationale for physicians prescribing appropriate therapy.Methods: Viloxazine was evaluated in a series of in vitro binding and functional assays. Its effect on neurotransmitter levels in the brain was evaluated using microdialysis in freely moving rats.Results: We report the effects of viloxazine on serotoninergic (5-HT) system. In vitro, viloxazine demonstrated antagonistic activity at 5-HT2B and agonistic activity at 5-HT2C receptors, along with predicted high receptor occupancy at clinical doses. In vivo, viloxazine increased extracellular 5-HT levels in the prefrontal cortex (PFC), a brain area implicated in ADHD. Viloxazine also exhibited moderate inhibitory effects on the norepinephrine transporter (NET) in vitro and in vivo, and elicited moderate activity at noradrenergic and dopaminergic systems.Conclusion: Viloxazine’s ability to increase 5-HT levels in the PFC and its agonistic and antagonistic effects on certain 5-HT receptor subtypes, which were previously shown to suppress hyperlocomotion in animals, indicate that 5-HT modulating activity of viloxazine is an important (if not the predominant) component of its MoA, complemented by moderate NET inhibition. Supported by clinical data, these findings suggest the updated psychopharmacological profile of viloxazine can be best explained by its action as a serotonin norepinephrine modulating agent (SNMA).Keywords: viloxazine, ADHD, serotonin norepinephrine modulating agent, norepinephrine transporter, mechanism of action, SPN-812
